Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency

Autor: Debbie S. Deben, Luc J. J. Derijks, Bianca J. C. van den Bosch, Rob H. Creemers, Annick van Nunen, Adriaan A. van Bodegraven, Dennis R. Wong

Publikováno v: Metabolites, Vol 13, Iss 10, p 1054 (2023)

Tioguanine is metabolised by fewer enzymatic steps compared to azathioprine and mercaptopurine, without generating 6-methylmercaptopurine ribonucleotides. However, thiopurine S-methyl transferase (TPMT) plays a role in early toxicity in all thiopurin

Externí odkaz: https://doaj.org/article/5fbf9405476044e988f385599d3ddcd0

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study

Autor: Merve Sivridaş, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Römkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens, Luc J. J. Derijks

Publikováno v: Pharmaceutics, Vol 15, Iss 3, p 972 (2023)

There are limited data on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients treated with vedolizumab (VDZ). Although an exposure–response relation has been demonstrated in the post-induction phase, this relationship is

Externí odkaz: https://doaj.org/article/935e6f04083545d584795100813406b1

Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine

Autor: Azhar Ansari, Paul J. Boekema, Jeremy D. Sanderson, Chris J. J. Mulder, Ahmed B. Bayoumy, Simon Anderson, Luc J J Derijks, Aathavan Loganayagam

Publikováno v: Therapeutic Drug Monitoring, 43(5), 617-623. Lippincott Williams and Wilkins
Therapeutic Drug Monitoring
Bayoumy, A B, Mulder, C J J, Loganayagam, A, Sanderson, J D, Anderson, S, Boekema, P J, Derijks, L J J & Ansari, A R 2021, ' Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine ', Therapeutic Drug Monitoring, vol. 43, no. 5, pp. 617-623 . https://doi.org/10.1097/FTD.0000000000000869

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gut. It can be divided into 2 main diseases: Crohn's disease (CD) and ulcerative colitis (UC). In the past 25 years, novel biological therapies have emerged for the treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d91bff36457c63f2cc7e2087414107
https://research.vumc.nl/en/publications/8ab981e9-5851-49a7-8e73-096fa2e3e739

6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients

Autor: Berrie Meijer, Joany E. Kreijne, Sofia A. W. van Moorsel, Adriaan A. van Bodegraven, Nanne K. H. de Boer, Dennis R Wong, Gerd Bouma, Luc J J Derijks, Chris J. J. Mulder, C. Janneke van der Woude

Publikováno v: Journal of Gastroenterology and Hepatology (Australia), 32(6), 1183-1190. Wiley-Blackwell
Journal of Gastroenterology and Hepatology, 32(6), 1183-1190. Wiley-Blackwell Publishing Ltd
Meijer, B, Kreijne, J E, van Moorsel, S A W, Derijks, L J J, Bouma, G, Mulder, C J J, Wong, D R, van der Woude, C J, van Bodegraven, A A & de Boer, N K H 2017, ' 6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients ', Journal of Gastroenterology and Hepatology (Australia), vol. 32, no. 6, pp. 1183-1190 . https://doi.org/10.1111/jgh.13656

Background and Aim: Thiopurines have a favorable benefit–risk ratio in the treatment of inflammatory bowel disease. A feared adverse event of thiopurine therapy is myelotoxicity, mostly occurring due to toxic concentrations of the pharmacologically

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a787d8971eedf20839dd7a9438a3f263
https://doi.org/10.1111/jgh.13656

A value proposition for trough level-based anti-TNFα drug dosing

Autor: E. M. H. Schmitz, Maarten A. C. Broeren, D. van de Kerkhof, Luc J J Derijks, Volkher Scharnhorst

Publikováno v: Clinica Chimica Acta, 489, 89-95. Elsevier

Treatment of inflammatory bowel diseases and rheumatic disorders with anti-tumor necrosis factor alpha (TNFα) drugs is expensive, while a significant proportion of patients does not show adequate clinical response. Therapeutic drug monitoring (TDM)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9702b528150951b8e16ffad0947a3ec1
https://pubmed.ncbi.nlm.nih.gov/30521801